Drugs / BL-B01D1
Trials 53
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT05983432 | Aug 2023 → Apr 2030 expected | cervical cancer, endometrial cancer, esophageal cancer, head and neck squamous cell carcinoma +6 | SystImmune Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05470348 | Aug 2022 → Dec 2026 expected | breast cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05393427 | Feb 2022 → Dec 2025 overdue | malignant urinary system neoplasm | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05262491 | Feb 2022 → Dec 2026 expected | digestive system neoplasm | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05194982 | Nov 2021 → Dec 2026 expected | — | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07307053 | Jan 2026 → Jan 2029 expected | high grade malignant neoplasm, metastatic neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06618287 | Feb 2025 → Feb 2031 expected | breast cancer, lung cancer | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05803018 | Jun 2023 → Dec 2026 expected | female reproductive organ cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 226 trials | ||||||
| Phase 2 | NCT07825753 | Sep 2026 → Sep 2027 expected | breast cancer, pancreatic adenocarcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07797881 | Sep 2026 → Dec 2030 expected | nasopharyngeal carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07827261 | Sep 2026 → Dec 2028 expected | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06855771 | Sep 2025 → Dec 2028 expected | non-small cell lung carcinoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 2 | NCT07054567 | Aug 2025 → May 2027 expected | cervical cancer, endometrial cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06962787 | Jul 2025 → May 2027 expected | kidney cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06951464 | Jun 2025 → May 2027 expected | non-small cell lung carcinoma | Sichuan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06986785 | Jun 2025 → May 2027 expected | hepatocellular carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06978114 | Jun 2025 → May 2027 expected | biliary tract cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06787664 | Jan 2025 → Jun 2027 expected | chordoma | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06598787 | Oct 2024 → Oct 2026 expected | glioblastoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06471205 | Aug 2024 → Jul 2026 overdue | triple-negative breast carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06498986 | Jul 2024 → Jun 2027 expected | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06475300 | Jun 2024 → Jul 2026 overdue | nasopharyngeal carcinoma, non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06437509 | Jun 2024 → Jun 2026 overdue | small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06437522 | Jun 2024 → Jun 2026 overdue | head and neck squamous cell carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06405425 | May 2024 → May 2026 overdue | urothelial carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05956587 | Jan 2024 → Dec 2026 expected | nasopharyngeal carcinoma, non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06042894 | Dec 2023 → Dec 2026 expected | breast cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05965856 | Dec 2023 → Dec 2026 expected | urothelial carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06008054 | Nov 2023 → Dec 2026 expected | colorectal cancer, esophageal cancer, gastric cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05924841 | Nov 2023 → Dec 2026 expected | small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05990803 | Nov 2023 → Dec 2026 expected | cervical cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06006169 | Oct 2023 → Dec 2026 expected | head and neck squamous cell carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05880706 | Jul 2023 → Jul 2027 expected | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05785039 | Apr 2023 → Dec 2026 expected | urinary system neoplasm | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT07554456 | Jun 2026 → Dec 2028 expected | esophageal squamous cell carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07642024 | Jun 2026 → Dec 2032 expected | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07641855 | Jun 2026 → Dec 2028 expected | castration-resistant prostate carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 316 trials · 3 met primary | ||||||
| Phase 3 | NCT07729956 | Sep 2026 → Dec 2029 expected | triple-negative breast carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07783321 | Sep 2026 → Dec 2033 expected | nasopharyngeal carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07640789 | Aug 2026 → Dec 2030 expected | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07582315 | Jul 2026 → Dec 2028 expected | biliary tract cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07648914 | Jun 2026 → Dec 2028 expected | breast cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07502300 | Apr 2026 → Dec 2029 expected | small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06994195 | Aug 2025 → Jun 2027 expected | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06857175 | Mar 2025 → Jun 2027 expected | urothelial carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06838273 | Feb 2025 → Dec 2028 expected | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06500026 | Aug 2024 → Dec 2026 expected | small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06382142 | Jun 2024 → Jun 2026 overdue | triple-negative breast carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | Met primary |
| Phase 3 | NCT06382116 | May 2024 → May 2026 overdue | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06382129 | May 2024 → Dec 2026 expected | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06343948 | Apr 2024 → May 2026 overdue | hormone receptor-positive breast cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | Met primary |
| Phase 3 | NCT06304974 | Mar 2024 → May 2026 overdue | esophageal squamous cell carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | Met primary |
| Phase 3 | NCT06118333 | Dec 2023 → Nov 2026 expected | nasopharyngeal carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 48
All press releases naming this drug 64 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 55 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BL-B01D1 | “Izalontamab brengitecan (iza-bren; BL-B01D1) is a bispecific antibody-drug conjugate (ADC) targeting both EGFR and HER3, covalently linked to a topoisomerase I inhibitor payload.” NCT07825753 ↗ |
| Known as | BMS-986507 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06618287 ↗ |
| Known as | iza-bren | “Izalontamab brengitecan (iza-bren; BL-B01D1) is a bispecific antibody-drug conjugate (ADC) targeting both EGFR and HER3, covalently linked to a topoisomerase I inhibitor payload.” NCT07825753 ↗ |
| Known as | Izalontamab Brengitecan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06855771 ↗ |
| Route | Intravenous | “patients received intravenous BL-B01D1” PMID 38823410 ↗ May 2024 |
| Target | EGFR | “targeting EGFR and human epidermal growth factor receptor 3 (HER3)” PMID 41611210 ↗ Jan 2026 |